Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease

Satohiro Matsumoto, Hirosato Mashima Department of Gastroenterology, Saitama Medical Center, Jichi Medical University, Saitama, Japan Abstract: Anti-TNFα drugs have been shown to be effective for maintaining stable remission in patients with Crohn’s disease. However, some problem...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Matsumoto S, Mashima H
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://doaj.org/article/c95abb24c49043a797850f7a694777c1
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:c95abb24c49043a797850f7a694777c1
record_format dspace
spelling oai:doaj.org-article:c95abb24c49043a797850f7a694777c12021-12-02T04:25:54ZEfficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease1177-5491https://doaj.org/article/c95abb24c49043a797850f7a694777c12018-07-01T00:00:00Zhttps://www.dovepress.com/efficacy-of-ustekinumab-against-infliximab-induced-psoriasis-and-arthr-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Satohiro Matsumoto, Hirosato Mashima Department of Gastroenterology, Saitama Medical Center, Jichi Medical University, Saitama, Japan Abstract: Anti-TNFα drugs have been shown to be effective for maintaining stable remission in patients with Crohn’s disease. However, some problems have been identified during clinical use of this class of drugs, such as secondary treatment failure, in which the drugs become progressively less effective with time, and the development of paradoxical reactions such as psoriatic skin symptoms. Thus, while anti-TNFα drugs are used to treat psoriasis, they can sometimes also cause paradoxical psoriasis, characterized by the appearance of psoriasis-like eruptions, which has recently begun to attract attention. Furthermore, inflammatory bowel disease is not only associated with intestinal lesions, but also with a variety of extraintestinal manifestations, of which arthritis is relatively common. We encountered a case of Crohn’s disease with arthritis, as an extraintestinal manifestation, and paradoxical psoriasis caused by infliximab treatment, in which ustekinumab proved extremely effective, not only for alleviating the arthritis, but also against the skin manifestations. To the best of our knowledge, this is the first reported case of the efficacy of ustekinumab against paradoxical psoriasis and arthritis in a patient with Crohn’s disease. Keywords: ustekinumab, paradoxical psoriasis, infliximab, arthritis, Crohn’s diseaseMatsumoto SMashima HDove Medical PressarticleUstekinumabParadoxical psoriasisInfliximabArthritisCrohn’s diseaseMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 12, Pp 69-73 (2018)
institution DOAJ
collection DOAJ
language EN
topic Ustekinumab
Paradoxical psoriasis
Infliximab
Arthritis
Crohn’s disease
Medicine (General)
R5-920
spellingShingle Ustekinumab
Paradoxical psoriasis
Infliximab
Arthritis
Crohn’s disease
Medicine (General)
R5-920
Matsumoto S
Mashima H
Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease
description Satohiro Matsumoto, Hirosato Mashima Department of Gastroenterology, Saitama Medical Center, Jichi Medical University, Saitama, Japan Abstract: Anti-TNFα drugs have been shown to be effective for maintaining stable remission in patients with Crohn’s disease. However, some problems have been identified during clinical use of this class of drugs, such as secondary treatment failure, in which the drugs become progressively less effective with time, and the development of paradoxical reactions such as psoriatic skin symptoms. Thus, while anti-TNFα drugs are used to treat psoriasis, they can sometimes also cause paradoxical psoriasis, characterized by the appearance of psoriasis-like eruptions, which has recently begun to attract attention. Furthermore, inflammatory bowel disease is not only associated with intestinal lesions, but also with a variety of extraintestinal manifestations, of which arthritis is relatively common. We encountered a case of Crohn’s disease with arthritis, as an extraintestinal manifestation, and paradoxical psoriasis caused by infliximab treatment, in which ustekinumab proved extremely effective, not only for alleviating the arthritis, but also against the skin manifestations. To the best of our knowledge, this is the first reported case of the efficacy of ustekinumab against paradoxical psoriasis and arthritis in a patient with Crohn’s disease. Keywords: ustekinumab, paradoxical psoriasis, infliximab, arthritis, Crohn’s disease
format article
author Matsumoto S
Mashima H
author_facet Matsumoto S
Mashima H
author_sort Matsumoto S
title Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease
title_short Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease
title_full Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease
title_fullStr Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease
title_full_unstemmed Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease
title_sort efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with crohn’s disease
publisher Dove Medical Press
publishDate 2018
url https://doaj.org/article/c95abb24c49043a797850f7a694777c1
work_keys_str_mv AT matsumotos efficacyofustekinumabagainstinfliximabinducedpsoriasisandarthritisassociatedwithcrohnrsquosdisease
AT mashimah efficacyofustekinumabagainstinfliximabinducedpsoriasisandarthritisassociatedwithcrohnrsquosdisease
_version_ 1718401216586711040